Surgery and doxorubicin in dogs with hemangiosarcoma
Surgery and doxorubicin in dogs with hemangiosarcoma
复制标题
DOI：
10.1111/j.1939-1676.1996.tb02085.x
复制
发表时间：
1996-11-01
影响因子：
2.6
通讯作者：
Withrow, SJ
中科院分区：
文献类型：
--
作者：
Ogilvie, GK;Powers, BE;Withrow, SJ
在一项前瞻性研究中，研究人员对46只组织学证实的不同部位的血管肉瘤犬进行了前瞻性研究，以确定在肿瘤部分或完全切除后10至14天使用阿霉素辅助治疗（30mg /m(2) IV， 3周，共5次治疗）的疗效。数据分析包括假设影响治疗反应、无病间隔（DFI）或生存时间（ST）的变量信息。收集的其他信息包括年龄、性别、品种、体重、既往治疗、手术类型、原发肿瘤的位置、转移的存在、阿霉素的剂量、对阿霉素治疗的反应（完全或部分反应），以及以下组织学标准：总体分化、核多型性、坏死百分比、有丝分裂评分、总组织学评分和分级。手术结果（完全或不完全手术切除）显著影响生存时间（P < 0.001）。20%的无病犬在1年后存活，而手术后有残留肿瘤的犬在1年后没有存活。对于完全切除肿瘤的犬，大多数组织学标准（核多形性、有丝分裂评分、分级、总体分化）与ST有显著（P < 0.05）或接近显著的独立相关性。DFI分析结果与完全切除肿瘤犬的ST分析结果大致相似。46只狗中有27只（58.7%）具有成功切除肿瘤的所有临床证据。手术结果（切除所有可见肿瘤的能力）的Logistic回归分析表明，年龄是唯一显著影响手术结果的因素（P = 0.017）。随着年龄的增长，成功的可能性增加，那些以前接受过血管肉瘤治疗的狗倾向于有更短的DFI和Si （P = .08）。因此，完全切除所有肿瘤证据，然后给予5剂量的阿霉素可能是血管肉瘤狗的有效治疗方法。成功切除所有肿瘤的狗的平均生存期和中位生存期分别为267天和172天。不完全肿瘤切除犬的平均生存期和中位生存期分别为172天和60天。同样，预后变量，如完全切除所有肿瘤证据的能力、组织学标准和患者年龄，都是预测预后的潜在重要预后变量。版权所有(C) 1996年由美国兽医内科学院。
Forty-six dogs with histologically confirmed hemangiosarcoma of various locations other than skin were used in a prospective study to determine the efficacy of adjuvant doxorubicin (30 mg/m(2) IV q 3 weeks for 5 treatments) 10 to 14 days after the tumor was partially or completely excised. Analysis of the data included information on variables that were hypothesized to influence response to therapy, disease-free interval (DFI), or survival time (ST). Other information collected included age, gender, breed, weight, prior therapy, type of surgery, location of the primary tumor, presence of metastases, number of doses of doxorubicin, response to doxorubicin therapy (complete or partial response), and the following histological criteria: overall differentiation, nuclear pleomorphism, percent necrosis, mitotic score, total histological score, and grade. Surgery outcome (complete versus incomplete surgical excision) markedly influenced survival times (P < .001). Twenty percent of the dogs rendered free of disease were alive at 1 year, whereas none of the dogs that had residual tumor after surgery were alive at 1 year. Most of the histological criteria (nuclear pleomorphism, mitotic score, grade, overall differentiation) had marked (P < .05), or close to marked, independent associations with ST for dogs that had complete tumor removal. Results from analysis of DFI were generally similar to those of ST in dogs with complete excision of the tumor. Twenty-seven of the 46 dogs (58.7%) had ail clinical evidence of tumor successfully removed. Logistic regression analysis of surgical outcome (ability to remove all visible tumor) suggested that age of the subject was the only factor markedly influencing surgical outcome (P = .017). As age increased, the probability of success increased, Those dogs that had previous treatment for their hemangiosarcoma tended (P = .08) to have a shorter DFI and Si. Therefore, complete removal of all evidence of tumor followed by 5 doses of doxorubicin may be an effective treatment for dogs with hemangiosarcoma. Dogs that had all tumor successfully removed had a mean and median ST of 267 and 172 days, respectively. Dogs with incomplete tumor removal had a mean and median ST of 172 and 60 days, respectively. Similarly, prognostic variables such as the ability to completely excise all evidence of tumor, histological criteria, and age of the patient are potentially important prognostic variables for predicting outcome. Copyright (C) 1996 by the American College of Veterinary Internal Medicine.